Drugs / lilotomab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02657447 | Dec 2017 → Sep 2019 | non-Hodgkin lymphoma | Nordic Nanovector | Withdrawn | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT02658968 Background | Mar 2017 → Jun 2021 | diffuse large B-cell lymphoma | Nordic Nanovector | Completed | No outcome recorded |
| Phase 1/2 | NCT01796171 Background | Dec 2012 → Oct 2022 | follicular lymphoma | Nordic Nanovector | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | lilotomab | “Dose finding study, starting on 10 MBq/kg b.w. Betalutin® (lutetium (177Lu)-lilotomab satetraxetan), single injection with lilotomab pre-dosing.” NCT02658968 ↗ |
| Modality | Monoclonal antibody | “the "cold" anti-CD37 antibody lilotomab” PMID 32877524 ↗ Sep 2020 |